Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 1/20 | 0.59 |
| ▸ | HCAR3 | P49019 | 4/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | ERN1 | O75460 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1110902 | 0.87 | HCAR3 (0.70) | VCAM1HCAR3HPGDKMT2AALDH1A1 | |
| SCHEMBL11757917 | 0.81 | LMNA (0.54) | VCAM1HCAR3KMT2AALDH1A1LMNA | |
| SCHEMBL9248825 | 0.80 | VCAM1 (0.50) | VCAM1HCAR3HPGDKMT2AALDH1A1 | |
| SCHEMBL9631242 | 0.80 | VCAM1 (0.58) | VCAM1HCAR3HPGDKMT2AALDH1A1 | |
| SCHEMBL11976724 | 0.79 | VCAM1 (0.57) | VCAM1HCAR3HPGDKMT2AALDH1A1 | |
| SCHEMBL21250340 | 0.79 | VCAM1 (0.57) | VCAM1HCAR3HPGDKMT2AALDH1A1 | |
| SCHEMBL5734347 | 0.79 | VCAM1 (0.68) | VCAM1HPGDKMT2AALDH1A1NPSR1 | |
| SCHEMBL29441708 | 0.78 | VCAM1 (0.53) | VCAM1HCAR3HPGDKMT2AALDH1A1 | |
| SCHEMBL17086143 | 0.78 | VCAM1 (0.53) | VCAM1HCAR3HPGDKMT2AALDH1A1 | |
| SCHEMBL3378050 | 0.78 | ALDH1A1 (0.53) | HPGDKMT2AALDH1A1NPSR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023733-A1 | Piperidine Derivatives, Their Process for Preparation, Their Use as Therapeutic Agents and Pharmaceutical Compositions Containing Them | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| EP-1994002-A1 | PIPERIDINE DERIVATIVES, THEIR PROCESS FOR PREPARATION, THEIR USE AS THERAPEUTIC AGENTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AstraZeneca AB (SE) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007102767-A1 | PIPERIDINE DERIVATIVES, THEIR PROCESS FOR PREPARATION, THEIR USE AS THERAPEUTIC AGENTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ASTRAZENECA AB (SE) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023733-A1 | Piperidine Derivatives, Their Process for Preparation, Their Use as Therapeutic Agents and Pharmaceutical Compositions Containing Them | CCR3, CCR1, CCR5 | VCAM1 142/4885HCAR3 71/4885HPGD 805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.